FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1982343418> ?p ?o ?g. }

• W1982343418 endingPage "326" @default.
• W1982343418 startingPage "313" @default.
• W1982343418 abstract "Despite innumerable trials of surgery, radiotherapy, and countless chemotherapeutic drugs, it is unclear whether any intervention has had a significant impact on more than a few highly selected patients with malignant pleural mesothelioma. Because most patients die of respiratory failure from extensive disease progression in the thorax, treatment usually includes attempts at local control. Unfortunately, radiotherapy is associated with significant complications in pleural mesothelioma, and surgery is feasible in only a small percentage of patients. Although there have been several single-institution reports of combined-modality therapy with extrapleural pneumonectomy, postoperative radiation, and chemotherapy in which prolonged survival has been observed, most patients with malignant pleural mesothelioma have locally advanced disease, advanced age, or comorbid medical illnesses that preclude aggressive surgery. Therefore, the use of a systemic anticancer agent is the only treatment option for most patients with malignant pleural mesothelioma. Evaluation of effective chemotherapy regimens for this disease has been hampered by many factors. Because mesothelioma is an uncommon malignancy, most studies have enrolled small numbers of patients, and few trials have been randomized. The disease is heterogenous, yet until recently there was no single staging system that could reliably predict survival, nor is there a universally accepted set of prognostic criteria for selecting a uniform group of patients. Response assessment has been limited by the inherent difficulties of reproducibly measuring pleural-based disease. The real impact of systemic chemotherapy on the natural history of malignant mesothelioma is still uncertain because phase III trials comparing chemotherapy with best supportive care have not yet been completed. Although nearly every class of cytotoxic agent has been evaluated in mesothelioma, response rates of greater than 20% have not been consistently demonstrated for any drug. The most active drug classes are the antifolates, the anthracyclines, and the platinums. Doxorubicin has historically been considered the gold-standard chemotherapy, although its true response rate is likely only 15%. The most active commercially available drug for mesothelioma so far appears to be gemcitabine. Although gemcitabine has a limited role as a single agent, it is quite active in combination with a platinating agent. The impressive 48% response rate reported for the combination of gemcitabine with cisplatin in a single phase II study has made this regimen the new standard of care for off-protocol treatment of this disease, although this trial still requires validation. With the recent introduction of several new agents with definite activity in this disease, the therapeutic nihilism previously associated with malignant pleural mesothelioma is gradually being replaced by a cautious optimism. Early trials of angiogenesis inhibitors, gene therapy, and vaccines offer additional avenues for treatment. As we begin to incorporate these active new drugs with each other and in adjuvant and neoadjuvant treatment regimens, there is reason to believe that superior results for patients with malignant pleural mesothelioma can be achieved in the near future." @default.
• W1982343418 created "2016-06-24" @default.
• W1982343418 creator A5090156519 @default.
• W1982343418 date "2000-08-01" @default.
• W1982343418 modified "2023-10-16" @default.
• W1982343418 title "Malignant pleural mesothelioma" @default.
• W1982343418 cites W1518820089 @default.
• W1982343418 cites W1836606828 @default.
• W1982343418 cites W1897113776 @default.
• W1982343418 cites W1936937687 @default.
• W1982343418 cites W1948574410 @default.
• W1982343418 cites W1960348144 @default.
• W1982343418 cites W1966381243 @default.
• W1982343418 cites W1971934196 @default.
• W1982343418 cites W1973252967 @default.
• W1982343418 cites W1975257575 @default.
• W1982343418 cites W1976854607 @default.
• W1982343418 cites W1993568439 @default.
• W1982343418 cites W2018302310 @default.
• W1982343418 cites W2021219775 @default.
• W1982343418 cites W2022538901 @default.
• W1982343418 cites W2028701020 @default.
• W1982343418 cites W2037466909 @default.
• W1982343418 cites W2045184976 @default.
• W1982343418 cites W2050014528 @default.
• W1982343418 cites W2053847483 @default.
• W1982343418 cites W2058414507 @default.
• W1982343418 cites W2077248800 @default.
• W1982343418 cites W2081508876 @default.
• W1982343418 cites W2095392215 @default.
• W1982343418 cites W2125980018 @default.
• W1982343418 cites W2148659149 @default.
• W1982343418 cites W2153219264 @default.
• W1982343418 cites W2163456861 @default.
• W1982343418 cites W2164644055 @default.
• W1982343418 cites W2165538729 @default.
• W1982343418 cites W2172010513 @default.
• W1982343418 cites W2242746637 @default.
• W1982343418 cites W2943505267 @default.
• W1982343418 cites W3148471154 @default.
• W1982343418 cites W4245078462 @default.
• W1982343418 cites W4245520901 @default.
• W1982343418 cites W4250098627 @default.
• W1982343418 cites W4375939011 @default.
• W1982343418 cites W2395826356 @default.
• W1982343418 doi "https://doi.org/10.1007/s11864-000-0047-4" @default.
• W1982343418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12057157" @default.
• W1982343418 hasPublicationYear "2000" @default.
• W1982343418 type Work @default.
• W1982343418 sameAs 1982343418 @default.
• W1982343418 citedByCount "37" @default.
• W1982343418 countsByYear W19823434182012 @default.
• W1982343418 countsByYear W19823434182013 @default.
• W1982343418 countsByYear W19823434182014 @default.
• W1982343418 countsByYear W19823434182016 @default.
• W1982343418 countsByYear W19823434182018 @default.
• W1982343418 countsByYear W19823434182021 @default.
• W1982343418 crossrefType "journal-article" @default.
• W1982343418 hasAuthorship W1982343418A5090156519 @default.
• W1982343418 hasBestOaLocation W19823434181 @default.
• W1982343418 hasConcept C105702510 @default.
• W1982343418 hasConcept C126322002 @default.
• W1982343418 hasConcept C141071460 @default.
• W1982343418 hasConcept C142724271 @default.
• W1982343418 hasConcept C143998085 @default.
• W1982343418 hasConcept C2776178081 @default.
• W1982343418 hasConcept C2776256026 @default.
• W1982343418 hasConcept C2776517811 @default.
• W1982343418 hasConcept C2776694085 @default.
• W1982343418 hasConcept C2777240266 @default.
• W1982343418 hasConcept C2777407522 @default.
• W1982343418 hasConcept C2777589429 @default.
• W1982343418 hasConcept C2777714996 @default.
• W1982343418 hasConcept C2778239845 @default.
• W1982343418 hasConcept C2779134260 @default.
• W1982343418 hasConcept C2779399171 @default.
• W1982343418 hasConcept C2910444461 @default.
• W1982343418 hasConcept C509974204 @default.
• W1982343418 hasConcept C535046627 @default.
• W1982343418 hasConcept C71924100 @default.
• W1982343418 hasConcept C97834683 @default.
• W1982343418 hasConceptScore W1982343418C105702510 @default.
• W1982343418 hasConceptScore W1982343418C126322002 @default.
• W1982343418 hasConceptScore W1982343418C141071460 @default.
• W1982343418 hasConceptScore W1982343418C142724271 @default.
• W1982343418 hasConceptScore W1982343418C143998085 @default.
• W1982343418 hasConceptScore W1982343418C2776178081 @default.
• W1982343418 hasConceptScore W1982343418C2776256026 @default.
• W1982343418 hasConceptScore W1982343418C2776517811 @default.
• W1982343418 hasConceptScore W1982343418C2776694085 @default.
• W1982343418 hasConceptScore W1982343418C2777240266 @default.
• W1982343418 hasConceptScore W1982343418C2777407522 @default.
• W1982343418 hasConceptScore W1982343418C2777589429 @default.
• W1982343418 hasConceptScore W1982343418C2777714996 @default.
• W1982343418 hasConceptScore W1982343418C2778239845 @default.
• W1982343418 hasConceptScore W1982343418C2779134260 @default.
• W1982343418 hasConceptScore W1982343418C2779399171 @default.
• W1982343418 hasConceptScore W1982343418C2910444461 @default.

• next